Clarification


FREE PREVIEW. AAFP members and paid subscribers: Log in to get free access. All others: Purchase online access.


FREE PREVIEW. Purchase online access to read the full version of this article.

Am Fam Physician. 2012 Jun 1;85(11):1024.

In the article, “Treatment of Alzheimer Disease” (June 15, 2011, page 1403), the first clinical recommendation in the Strength of Recommendation Taxonomy (SORT) table (page 1404) was not as complete or balanced as it should have been. The recommendation, “Acetylcholinesterase inhibitors should be considered first-line therapy for patients with mild to moderate Alzheimer disease,” should have mentioned the adverse effects associated with this drug class. The revised recommendation should read: “Acetylcholinesterase inhibitors are modestly effective in patients with mild to moderate Alzheimer disease, although limited by their adverse effects.” The article has been corrected online.


Copyright © 2012 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Information From Industry

More in Pubmed

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article